Examples of 'ibritumomab tiuxetan' in a sentence
Meaning of "ibritumomab tiuxetan"
Ibritumomab tiuxetan is a type of medication used in the treatment of certain types of non-Hodgkin lymphoma. It is a radioimmunotherapy drug that combines a radioactive substance with an antibody, targeting and killing cancer cells in the body. It is usually administered intravenously and requires careful medical supervision
Show more definitions
- A monoclonal antibody radioimmunotherapy treatment for some forms of B-cell non-Hodgkin lymphoma.
How to use "ibritumomab tiuxetan" in a sentence
Basic
Advanced
ibritumomab tiuxetan
Mg ibritumomab tiuxetan in sodium chloride solution.
It is not known whether ibritumomab tiuxetan is excreted in milk.
Animal reproduction studies were not conducted with ibritumomab tiuxetan.
Transfer ibritumomab tiuxetan solution to the reaction vial.
The active substance is ibritumomab tiuxetan.
One ibritumomab tiuxetan vial.
Zevalin is a kit for the preparation of the active substance ibritumomab tiuxetan.
Ibritumomab tiuxetan solution.
Minimum particulars to appear on small immediate packaging units ibritumomab tiuxetan solution vial.
Ibritumomab tiuxetan vial, Clear colourless solution.
The kit allows the coupling of antibody ibritumomab tiuxetan with the radioactive isotope yttrium.
Rituximab pretreatment is necessary to clear circulating B-cells, enabling ibritumomab tiuxetan.
The kit allows the coupling of antibody ibritumomab tiuxetan with the radioactive isotope yttrium 90Y radiolabelling.
Ibritumomab tiuxetan vial, Sodium chloride Water for injections.
EPAR summary for the public ibritumomab tiuxetan.
See also
Y ibritumomab tiuxetan in a total volume of 10 ml.
Includes suggestions for Ibritumomab tiuxetan.
In the ibritumomab tiuxetan vial, sodium chloride, water for injection.
In one embodiment, the antibody is ibritumomab tiuxetan.
One ibritumomab tiuxetan glass vial, with 2 ml clear, colourless solution.
Zevalin is supplied as a kit for the preparation of yttrium-90 radiolabelled ibritumomab tiuxetan.
Step 3, Transfer ibritumomab tiuxetan solution to the reaction vial.
A method according to embodiment 117, wherein the FcR binding peptide is ibritumomab tiuxetan.
Ml of solution of ibritumomab tiuxetan in a vial ( type I glass ) with a rubber stopper teflon-lined bromobutyl.
Zevalin 1.6 mg / ml kit for radiopharmaceutical preparations Ibritumomab tiuxetan solution.
Ibritumomab tiuxetan is a recombinant murine IgG1 kappa monoclonal antibody specific for the B-cell antigen CD20.
Zevalin 1.6 mg / ml kit for radiopharmaceutical preparations for infusion Ibritumomab tiuxetan.
Zevalin 1.6 mg / ml kit for radiopharmaceutical preparations Ibritumomab tiuxetan solution Intravenous infusion, after preparation.
Ibritumomab tiuxetan vial, type I glass vial with a rubber stopper ( teflon-lined bromobutyl ) containing 2 ml solution.
Y-radiolabelled Zevalin, the median serum effective half-life of ibritumomab tiuxetan.
Ibritumomab tiuxetan is a recombinant murine IgG1 kappa monoclonal antibody specific for the B - cell antigen CD20.
Examples of these radioactive molecules include ibritumomab tiuxetan ( Zevalin ) and tositumomab ( Bexxar ).
In some aspects of the disclosure, the anti-CD20 antibody is ofatumumab, ublituximab, and / or ibritumomab tiuxetan.
Incubate the yttrium-90 chloride / acetate / ibritumomab tiuxetan solution at room temperature for five minutes.
Zevalin 1.6 mg / ml Kit for radiopharmaceutical preparation for infusion Ibritumomab tiuxetan.
Y-radiolabelled ibritumomab tiuxetan binds specifically to CD20-expressing B-cells, including malignant cells.
One vial contains 3.2 mg of ibritumomab tiuxetan.
The final formulation after radiolabelling contains 2.08 mg ibritumomab tiuxetan.
The final formulation after radiolabeling contains 2.08 mg ibritumomab tiuxetan in a total volume of 10 ml.
